Characterization of an antineoplastic glucuronide prodrug

Biochemical Pharmacology

Volumn 58, Issue 2, 1999, Pages 325-328

  Cheng, Tian Lu ^a,b   Chou, Wan Chih ^a,b   Chen, Bing Mae ^b   Chern, Ji Wang ^c   Roffler, Steve R ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Glucuronidase; ADEPT; Cancer; Internalization; Monoclonal antibody; Partition coefficient; Prodrugs

Indexed keywords

4 [BIS(2 CHLOROETHYL)AMINO]PHENOL; 4[BIS(2 CHLOROETHYL)AMINO]PHENOL GLUCURONIDE; BETA GLUCURONIDASE; PRODRUG; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL STRAIN BHK; CYTOTOXICITY; DRUG ACTIVATION; DRUG UPTAKE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT;

ANILINE MUSTARD; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, ALKYLATING; GLUCURONATES; GLUCURONIDASE; HUMANS; PRODRUGS; RATS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033566279     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00072-6     Document Type: Article

References (15)

1. Senter P.D., Saulnier M.G., Schreiber G.J., Hirschberg D.L., Brown J.P., Hellström I., Hellström K.E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA. 85:1988;4842-4846.
2. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., Sherwood R.F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 58:1988;700-703.
3. Roffler S.R., Wang S.M., Chern J.W., Yeh M.Y., Tung E. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol. 42:1991;2062-2065.
4. Wang S.M., Chern J.W., Yeh M.Y., Ng J.C., Tung E., Roffler S.R. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52:1992;4484-4491.
5. Chen B.M., Chan L.Y., Wang S.M., Wu M.F., Chern J.W., Roffler S.R. Cure of malignant ascites and generation of protective immunity by monoclonal antibody targeted activation of a glucuronide prodrug in rats. Int J Cancer. 73:1997;392-402.
6. Cheng T.L., Chen B.M., Chan L.Y., Wu P.Y., Chern J.W., Roffler S.R. Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother. 44:1997;305-315.
7. Cheng T.L., Wei S.L., Chen B.M., Chern J.W., Wu M.F., Liu P.W., Roffler S.R. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br J Cancer. 79:1999;1378-1385.
8. Roffler S.R., Chan J., Yeh M.Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res. 54:1994;1276-1285.
9. Berendt A.R., McDowall A., Craig A.G., Bates P.A., Sternberg M.J.E., Marsh K., Newbold C.I., Hogg N. The binding site on ICAM-1 for Plasmodium falciparum-infected erythrocytes overlaps, but is distinct from, the LFA-1-binding site. Cell. 68:1992;71-81.
10. Fishman W.H., Goldman S.S., DeLellis R. Dual localization of β-glucuronidase in endoplasmic reticulum and in lysosomes. Nature. 213:1967;457-460.
11. Bock K.W. Roles of UDP-glucuronosyltransferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol. 26:1991;129-150.
12. Hellström I., Horn D., Linsley P., Brown J.P., Brankovan V., Hellström K.E. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 46:1986;3917-3923.
13. Colcher D., Hand P.H., Nuti M., Schlom J.A. Spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA. 78:1981;3199-3203.
14. Hayden M.S., Grosmaire L.S., Norris N.A., Gilliland L.K., Winberg G., Tritschler D., Tsu T.T., Linsley P.S., Mittler R.S., Senter P.D., Fell H.P., Ledbetter J.A. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens. 48:1996;242-254.
15. Starling J.J., Maciak R.S., Law K.L., Hinson N.A., Briggs S.L., Laguzza B.C., Johnson D.A. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Cancer Res. 51:1991;2965-2972.